ClinicalTrials.gg
RecruitingNCT07525466Updated Apr 13, 2026

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

A Phase 1/2 interventional study of Mitoxantrone liposome and Etoposide in Extranodal NK T Cell Lymphoma and Hemophagocytic Lymphohistiocytosis (HLH), sponsored by Beijing Tongren Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Beijing Tongren Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China — 22 open to participants now, 25 under way, 2 of them phase 3. Lymphoma, Extranodal NK-T-Cell · China.

Planned enrollment
50th of 65
25 · median 40
Started
2026
with 7 others
Phase 1/2
7 of 73
2 open now
Primary completion
2028-03
later than 16 of 24 live
Registered
67th of 73
by date
Lead sponsor
5 of 73
Beijing Tongren Hospital

Among the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, this one is the 50th largest by planned enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2026, is one of 7 in phase 1/2, reaches primary completion later than 16 of the 24 other live ones, and was the 67th registered.

Lymphoma, Extranodal NK-T-Cell

270 studies on the registry are indexed under Lymphoma, Extranodal NK-T-Cell; 36 are open to participants now.

Browse Lymphoma, Extranodal NK-T-Cell studies →

Open to participants now

22 of the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Lymphoma, Extranodal NK-T-Cell studies recruiting now, 11 (55%) set no upper age limit and 8 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, or all of them as a file.
02

Study summary

Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patients develop secondary hemophagocytic lymphohistiocytosis (NKTCL-HLH), a life-threatening complication with median survival \<2 months and mortality over 90%. Current treatments fail to simultaneously control lymphoma and hyperinflammation, with poor tolerance and high resistance.

The JAK/STAT pathway drives EBV-induced inflammation and tumor progression. Golidocitinib, a selective JAK1 inhibitor, demonstrates potent anti-NKTCL activity and rapid inflammation control. Liposomal mitoxantrone offers targeted efficacy with lower toxicity, while etoposide, methylprednisolone, and pegaspargase provide synergistic anti-tumor and anti-HLH effects.

This study proposes the novel MEPL-G regimen (liposomal mitoxantrone, etoposide, methylprednisolone, pegaspargase, golidocitinib) for NKTCL-HLH. By targeting both HLH and NKTCL, this combination aims to achieve rapid disease control, improve tolerance, and prolong survival, addressing the unmet critical clinical need for this high-risk population.

Read the detailed description

Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive Epstein-Barr virus (EBV)-associated non-Hodgkin lymphoma with particularly high incidence in Asia, especially in southern China where it accounts for 10%-15% of all malignant lymphomas. Early-stage NKTCL can achieve an 80% long-term survival rate with radiotherapy combined with pegaspargase-based chemotherapy. However, advanced and relapsed/refractory NKTCL carries a dismal prognosis, with long-term survival below 40%. A severe complication is hemophagocytic lymphohistiocytosis (HLH), which develops in 10%-20% of patients and leads to an extremely aggressive clinical course, with median survival less than 2 months and 6-month overall survival of only 23%.

Pathogenically, EBV infection induces abnormal immune activation through the JAK/STAT and NF-κB pathways, triggering a cytokine storm characterized by elevated IFN-γ, TNF-α, IL-6, and IL-10. This immune dysregulation, combined with impaired cytotoxic function, drives both lymphomagenesis and HLH progression. Current treatments remain unsatisfactory. Traditional HLH-directed regimens fail to control underlying lymphoma, while conventional lymphoma chemotherapy shows limited efficacy and poor tolerance due to multi-drug resistance and organ dysfunction.

Recently, targeted agents have emerged as promising strategies. Golidocitinib, a highly selective JAK1 inhibitor, effectively blocks JAK1-STAT3 signaling, suppresses EBV-driven tumor growth, and mitigates cytokine storms. It has demonstrated encouraging anti-tumor activity in relapsed/refractory NKTCL. Meanwhile, liposomal mitoxantrone improves tumor targeting and reduces cardiotoxicity, with objective response rates of 50%-60% in NKTCL. Etoposide, methylprednisolone, and pegaspargase further provide synergistic anti-lymphoma and anti-inflammatory effects.

Our research group has accumulated extensive experience in NKTCL and NKTCL-HLH, validating effective combination regimens and supporting the rationale of combining anti-lymphoma and anti-HLH strategies. Therefore, this study designed the innovative MEPL-G regimen (liposomal mitoxantrone, etoposide, methylprednisolone, pegaspargase, golidocitinib) for NKTCL-HLH patients. This regimen aims to rapidly control HLH, eradicate lymphoma, improve safety and tolerance, and ultimately prolong survival, addressing the urgent unmet medical need for this high-risk population.

03

Conditions studied

  • Extranodal NK T Cell Lymphoma
  • Hemophagocytic Lymphohistiocytosis (HLH)

Keywords

  • extranodal NK/T-cell lymphoma
  • hemophagocytic lymphohistiocytosis
  • Mitoxantrone Liposome
  • Golidocitinib
  • JAK1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed extranodal NK/T-cell lymphoma.
  • Meeting the HLH-2004 diagnostic criteria (≥ 5 criteria).
  • Age ≥ 18 years, regardless of gender.
  • Negative antigen or antibody.
  • (LVEF) ≥ 50% on cardiac echocardiography.
  • No active visceral bleeding (e.g., gastrointestinal, pulmonary, cerebral).
  • No uncontrolled infection (e.g., pulmonary infection, intestinal infection).
  • Negative antibody; or positive HCV antibody with negative HCV RNA.
  • Negative and negative HBcAb. If either is positive, peripheral blood HBV DNA load must be \< 1×10³ copies/mL to be eligible.
  • Signed written and ability to understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  • (NYHA) cardiac function class ≥ II;
  • Female patients who are pregnant or breastfeeding;
  • Known to any of the study drugs;
  • Presence of other concurrent (except non-melanoma skin cancer);
  • Concurrent central nervous system lymphoma infiltration;
  • Severe psychiatric disorders or inability to comply with follow-up;
  • Severe renal dysfunction ( \< 15 mL/min);
  • Severe liver cirrhosis (MELD score > 20);
  • History of acute or chronic pancreatitis;
  • Simultaneous participation in another clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    MEPL-G group

    All enrolled patients may initiate induction therapy with the MEPL-G regimen after completing baseline imaging and laboratory examinations. The detailed administration is as follows: Doses of etoposide, golidocitinib, pegaspargase, and methylprednisolone are fixed. The optimal dose of liposomal mitoxantrone will be determined based on dose-limiting toxicity (DLT). In the Phase Ib part, 3 patients will be enrolled at the starting dose of liposomal mitoxantrone: 18 mg/m²/d on day 1, every 3 weeks (q3w). If no DLT occurs, the recommended phase 2 dose (RP2D) will be 18 mg/m²/d on day 1 q3w. If DLT occurs, the dose will be de-escalated sequentially. One cycle is 3 weeks, for a total of 6 cycles. Patients achieving CR or PR after 2 cycles may be referred for allogeneic hematopoietic stem cell transplantation. Patients with CR or PR after 2 cycles who are ineligible for transplantation may continue MEPL-G for a total of 6 cycles, followed by maintenance therapy with golidocitinib monotherapy

    Drug: Mitoxantrone liposome · Drug: Etoposide · Drug: Pegaspargase (PEG) Asparaginase · Drug: methylprednisolone · Drug: golidocitinib

Interventions

  • DrugMitoxantrone liposome

    In the Phase Ib part, 3 patients will be enrolled at the starting dose of liposomal mitoxantrone: 18 mg/m²/d on day 1, every 3 weeks (q3w). If no DLT occurs, the recommended phase 2 dose (RP2D) will be 18 mg/m²/d on day 1 q3w. If DLT occurs, the dose will be de-escalated sequentially (18→16→14→12 mg/m²/d on day 1 q3w).

  • 100mg/m²/d,d1、d8,q3w

  • DrugPolyethylene GlycolsStudies of Polyethylene GlycolsPolyethylene Glycols pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2000IU/m²/d,d5,q3w

  • 15mg/kg/d,d1-3 7.5mg/kg/d,d4-7 1mg/kg/d d8-14 10mg/d,d15-21

  • 150mg/d,d1-d21,q3w

06

What researchers measure

Primary outcomes

  1. 6-month overall survival (OS) rate

    OS was defined from the date of initiation of MEPL-G to the date fo death.

    Time frame: From the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G

Secondary outcomes

  1. 6-month progression free survival (PFS) rate

    PFS was defined from the date of initiation of MEPL-G to the date of confirmed disease progression or death of any reason

    Time frame: From the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G

  2. overall response rate (ORR)

    Overall response rate means sum of complete response rate and partial response rate

    Time frame: from the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G.

  3. complete response (CR) rate

    CR was defined as complete response evaluated using PET-CT scan

    Time frame: from the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G.

  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    measured using CTCAE version 5.0

    Time frame: from the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Mar 2028, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 13, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Sep 30, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07525466
Responsible party
LIANG WANG (Director of Department of Hematology in Beijing Tongren Hospital, Beijing Tongren Hospital) — Principal investigator
First posted
Apr 13, 2026
Start date
Apr 1, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Liang Wang, M.D.
Contact
wangliangtrhos@126.com
+861058266633
Jia Cong, M.D.
Contact
congjia21@163.com
Liang Wang
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion